Skip to main content
SpringerLink
Log in

The Bleb Formation of the Extracellular Pseudopodia; Early Evidence Of Microtubule Depolymerization by Estramustine Phosphate in Glioma Cell; In Vitro Study

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Estramustine phosphate (EMP) is an anti-microtubule agent that depolymerizes microtubules and also causes apoptosis of glioma cells. Both of these pharmacological actions have been previously studied within the same cytotoxic range of EMP concentrations. The purpose of this study was to investigate which of these two phenomena occurred before the other. A preliminary MTT assay was done to distinguish non-cytotoxic (0.005–0.1 μM) and cytotoxic (0.5–10 μM) of EMP for BT4C cells. To investigate apoptotic changes, transmission electron microscopy (TEM), DNA laddering, and in situ endo-labeling (TUNEL) method were employed. A chemotaxis assay was used to assess cell motility. Scanning electron microscopy and TEM immunocytochemistry with an anti-β tubulin antibody were applied to detect morphological changes of the microtubules. Suppression of cell motility by cytotoxic doses of EMP (0.5–10 μM) group was attributed by the cyto-reductive effect, relating to apoptosis. At 0.01–0.1 μM (non-cytotoxic doses), EMP did not indue apoptosis. At these concentrations, TEM and immunohistochemistry revealed the formation of blebs on the tip of the pseudopodia that contained abnormally depolymerized microtubules, a finding that was not observed at a low temperature or during cell migration. Cell chemotaxis was significantly inhibited by cytostatic EMP doses (0.05 and 0.1 μM). Bleb formation of the pseudopodia might be evidence of the abnormal disassembly of microtubules by cytostatic EMP concentrations, prior to the induction of apoptosis. In glioma cells EMP probably initiates apoptosis by causing the depolymerization of microtubules. Inhibition of cell motility by cytostatic doses of EMP could be beneficial to support other therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kanje M, Deinum J, Wallin M, Ekstrom P, Edstrom A, Hartley-Asp B: Effect of estramustine phosphate on the assembly of isolated bovine brain microtubules and fast axon transport in the frog sciatic nerve. Cancer Res 45: 2234–2239, 1985

    Google Scholar 

  2. Kim JH, Khil MS, Ryu S, Gabel M: Clinical and biological studies of estramustine phosphate as a radiation sensitizer. Int J Radiat Oncol Biol Phys 29: 555–557, 1994

    Google Scholar 

  3. Forsgren B, Björk P: Specific binding of estramustine to prostatic proteins. J Urol 23: 31–38, 1984

    Google Scholar 

  4. Gunnarsson PO, Andersson SB, Sandberg AA, Ellman M: Accumulation of estramustine and estromustine in adipose tissue of rats and humans. Cancer Chemother Pharmacol 28: 361–364, 1991

    Google Scholar 

  5. Bergenheim AT, Gunnarsson PO, Edman K, Schoultz Ev, Hariz M: Uptake and retension of estramustine and presence of estramustine binding protein in malignant brain tumours in humans. Br J Cancer 67: 358–361, 1993

    Google Scholar 

  6. Bergenheim AT, Bjork P, Bergh J, von-Schoultz E, Svedberg H, Henriksson R: Estramustine-binding and specific binding protein of the anti-mitotic compound estramustine in astrocytoma. Cancer Res 54: 4974–4979, 1994

    Google Scholar 

  7. Johansson M, Bergenheim A, D'Argy R, Edman K, Gunnarsson P, Wildmark A, Henriksson R: Distribution of estramustine in the BT4C rat glioma model. Cancer Chemother Pharmacol 41: 317–325, 1998

    Google Scholar 

  8. von-Shoultz E, Begenheim T, Grankvist K, Henriksson R: Estramustine binding protein in human brain-tumor tissue. J Neurosurg 74: 962–964, 1991

    Google Scholar 

  9. Behnam-Motlagh P, Jonsson O, Engstrom K, Henriksson R, Grankvist K: Computerized detection of morphological changes to glioma cells during estramustine and ion-channel blocker perifusion. Br J Cancer 76: 318–324, 1997

    Google Scholar 

  10. Yoshida D, Cornell-Bell A, Piepmeier JM: Selective antimitotic effects of estramustine correlate with its antimicrotubule properties on glioblastoma and astrocytes. Neurosurgery 34: 863–868, 1994

    Google Scholar 

  11. Johansson M, Bergenheim A, Widmark A, Henriksson R: Effects of radiotherapy and estramustine on the microvasculature in malignant glioma. Br J Cancer 80: 142–148, 1999

    Google Scholar 

  12. Ryu S, Gabel M, Khil MS, Lee YJ, Kim SH, Kim JH: Estramustine: a novel radiation enhancer in human carcinoma cells. Int J Radiat Oncol Biol Phys 30: 99–104, 1994

    Google Scholar 

  13. Yoshida D, Piepmeier JM, Weinstein M: Estramustine sensitizes human glioblastoma cells to irradiation. Cancer Res 54: 1415–1417, 1994

    Google Scholar 

  14. Piepmeier JM, Keefe DL, Weinstein MA, Yoshida D, Zielinski J, Lin TT, Chen Z, Naftolin F: Estramustine and estrone analogs rapidly and reversibly inhibit deoxyribonucleic acid synthesis and alter morphology in cultured human glioblastoma cells. Neurosurgery 32: 422–431, 1993

    Google Scholar 

  15. Bergenheim A, Henriksson R, Piepmeier JM, Yoshida D: Estramustine in malignant glioma. J Neuro-Oncol 30: 81–89, 1996

    Google Scholar 

  16. Bergenheim A, Henriksson R: Pharmacokinetics and pharmacodynamics of estramustine phosphate (Review). Clinical Pharmacokinetics 34: 163–172, 1998

    Google Scholar 

  17. Pedrotti B, Islam K: Estramustine phosphate but not estramustine inhibits the interaction of microtubule associated protein 2 (MAP2) with actin filaments. FEBS Lett 403: 123–126, 1997

    Google Scholar 

  18. Vallbo C, Bergenheim A, Bergh A, Grankvist K, Henriksson R: DNA fragmentation induced by the antimitotic drug estramustine in malignant rat glioma but not in normal brain - suggesting an apoptotic cell death. Br J Cancer 71: 717–720, 1995

    Google Scholar 

  19. Yoshida D, Shimura T, Takahashi H, Hoshino S, Aihara K, Teramoto A: Drug-induced apoptosis by antimicrotubule agent, estramustine phosphate on human malignant glioma cell line, U87MG; in vitro study. J Neuro-Oncol 47: 133–140, 2000.

    Google Scholar 

  20. Haldar S, Chintappalli J, Croce CM: Taxol induces Bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56: 1253–1255, 1996

    Google Scholar 

  21. Kondoh M, Usui T, Nishikiori T, Mayumi T, Osada H: Apoptosis induction via microtubule disassembly by an antitumor compound, pironectin. Biochem J 340: 411–416, 1999

    Google Scholar 

  22. Engstrom KG, Grankvist K, Henriksson R: Early morphological detection of estramustine cytotoxity measured as alteration in cell size and shape by a new technique of microperifusion. Eur J Cancer 27: 1288–1295, 1991

    Google Scholar 

  23. Panda D, Miller H, Islam K, Wilson L: Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: a possible mechanistic basis for its antitumor action. Proc Natl Acad Sci USA 94: 10,560–10,564, 1997

    Google Scholar 

  24. Piepmeier J, Pedersen P, Yoshida D, Greer C: Targeting microtubule-associated proteins in glioblastoma: a new strategy fro selective therapy. Ann Surg Oncol 3: 543–549, 1996

    Google Scholar 

  25. Yoshida D, Piepmeier J, Bergenheim A, Henriksson R, Teramoto A: Suppression of matrix metalloproteinase-2-mediated cell invasion in U87MG, human glioma cells by anti-microtubule agent; in vitro study. Br J Cancer 77: 21–25, 1998

    Google Scholar 

  26. Fisher D: Apoptosis in cancer therapy. Cell 78: 539–542, 1994

    Google Scholar 

  27. Motyl T: Regulation of apoptosis: involvement of Bcl-2-related proteins. Reprod Nutr Dev 39: 49–59, 1999

    Google Scholar 

  28. Nikkahah G, Tonn J, Hoffmann O, Kraemer H, Darling J, Schonmayr R, Schachenmayr W: The MTT assay for chemosensitivity testing of human tumors of the central nervous system. J Neuro-Oncol 13: 1–11, 1992

    Google Scholar 

  29. Giese A, Rief M, Loo M, Berens M: Determinants of human astrocytoma migration. Cancer Res 54: 3897–3904, 1994

    Google Scholar 

  30. Muir D, Sukhu L, Johnson J, Lahorra M, Maria B: Quantitative methods for scoring cell migration and invasion in filter-based assays. Anal Biochem 215: 104–109, 1993

    Google Scholar 

  31. Lin CH, Forscher P: Cytoskeleton remodeling during growth cone-target interactions. J Cell Biol 121: 1369–1383, 1993

    Google Scholar 

  32. Singh S, Gao Y, Singh L, Kunapuli S, Ravindra R: Role of microtubules in glucose uptake by C6 glioma cell. Pharmacol Toxicol 83: 83–89, 1998

    Google Scholar 

  33. McGuire W, Rownski E, Rosenshein N, Grumbie F, Ettinger D, Armstrong D, Donehower R: Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Int Med 111: 273–279, 1989

    Google Scholar 

  34. Weller M, Trepel M, Grimmel C, Schabet M, Bremen D, Krajewski S, Reed J: Hypericin-induced apoptosis of human maligant gloma cells is light-dependent, independent of Bcl-2 expression, and does not require wild-type p53. Neurog Res 19: 459–470, 1997

    Google Scholar 

  35. Woods C, Zhu J, McQueney P, Bollag D, Lazarides E: Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med 1: 506–526, 1995

    Google Scholar 

  36. Yoshida D, Piepmeier JM, Teramoto A: In vitro inhibition of cell proliferation, viability, and invasiveness in U87MG human glioblastoma cells by estramustine phosphate. Neurosurgery 39: 360–366, 1996

    Google Scholar 

  37. Sahenk Z, Mendell J: Alteration in slow transport kinetics induced by estramustine, an agent binding to microtubule-associated proteins. J Neurosci Res 32: 481–493, 1992

    Google Scholar 

  38. Santell L, Marotti K, Bartfeld N, Baynham P, Levin E: Disruption of microtubules inhibits the stimulation of tissue plasminogen activator expression and promotes plasminogen activator inhibitor type 1 expression in human endothelial cells. Exp Cell Res 201: 358–365, 1992

    Google Scholar 

  39. Mohanam S, Sawaya R, McCutcheon I, Ali-Osman F, Boyd D, Rao J: Modulation of in vitro of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. Cancer Res 53: 4143–4147, 1993

    Google Scholar 

  40. Johansson M, Bergenheim A, Henriksson R, Koskinen L, Vallbo C, Wildmark A: Tumor blood flow and the cytotoxic effects of estramustine and its constituents in a rat glioma model. Neurosurgery 41: 237–244, 1997

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Nippon Medical School, Sendagi, Bunkyo-Ku, Tokyo, Japan

    Daizo Yoshida, Masahiro Noha, Kunihiro Watanabe, Tommy Bergenheim & Akira Teramoto

  2. Department of Oncology, Umeå University Hospital, Sweden

    Roger Henriksson

Authors
  1. Daizo Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masahiro Noha
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kunihiro Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tommy Bergenheim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Roger Henriksson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Akira Teramoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yoshida, D., Noha, M., Watanabe, K. et al. The Bleb Formation of the Extracellular Pseudopodia; Early Evidence Of Microtubule Depolymerization by Estramustine Phosphate in Glioma Cell; In Vitro Study. J Neurooncol 52, 37–47 (2001). https://doi.org/10.1023/A:1010653613588

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1010653613588

Search

Navigation